Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.94 |
| ▸ | RAD52 | P43351 | 2/20 | 0.94 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372738 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL15965174 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8381473 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386909 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1172093 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8383501 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL1171874 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL6375709 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL8386779 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL37593 | 1.00 | DNM1 (1.00) | DNM1HTTKMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588586-B1 | COMPATIBLE MIXTURES OF ANIONIC AND CATIONIC SURFACTANTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | claimed |
| EP-1661586-B1 | Disinfecting substrate | BODE CHEMIE GMBH (DE) | 2010-08-04 | — | — | EP | claimed |
| US-20100187113-A1 | CAPILLARY SIEVING ELECTROPHORESIS WITH A CATIONIC SURFACTANT FOR SIZE SEPARATION OF PROTEINS | DOLNIK VLADISLAV | 2010-07-29 | — | — | US | claimed |
| CN-100491450-C | Chitosan quaternary ammonium salt/organic rectorite composite material and its preparing method | UNIV WUHAN (CN) | 2009-05-27 | — | — | CN | claimed |
| WO-2009048962-A1 | CAPILLARY SIEVING ELECTROPHORESIS WITH A CATIONIC SURFACTANT FOR SIZE SEPARATION OF PROTEINS | DOLNIK VLADISLAV (US) | 2009-04-16 | — | — | WO | claimed |
| CN-1986622-A | Nano chitosan quaternary ammonium salt/organic rectorite composite material and its preparing method | UNIV WUHAN (CN) | 2007-06-27 | — | — | CN | claimed |
| EP-1027880-B1 | Use of quaternary ammonium compounds as antiperspirants | BEIERSDORF AG (DE) | 2005-07-13 | — | — | EP | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-4531576-A1 | AQUEOUS DETERGENT AND/OR DISINFECTANT COMPOSITION | Sodel (FR) | 2025-04-09 | — | — | EP | disclosed |
| US-20250019482-A1 | SYNTHESIS AND FABRICATION OF MECHANICALLY ROBUST AND MESOPOROUS ABAC TETRABLOCK POLYMER MEMBRANES FOR ULTRAFILTRATION | U.S. DEPARTMENT OF ENERGY | 2025-01-16 | — | — | US | disclosed |
| WO-2024142752-A1 | LIQUID DETERGENT ARTICLE | ライオン株式会社 | 2024-07-04 | — | — | WO | disclosed |
| US-11914295-B2 | Thermosetting iodine- and silicon-containing material, composition containing the material for forming resist underlayer film for EUV lithography, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| WO-2023233105-A1 | AQUEOUS DETERGENT AND/OR DISINFECTANT COMPOSITION | SODEL (FR) | 2023-12-07 | — | — | WO | disclosed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5538893-A | USING MIXTURE OF NONIONIC AND CATIONIC SURFACTANT AND BUFFER | TOA MEDICAL ELECTRONICS CO., LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0678743-A1 | Reagent for analyzing leukocytes and a method for classifying leukocytes | TOA MEDICAL ELECTRONICS CO., LTD. (JP) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11914295-B2 | Thermosetting iodine- and silicon-containing material, composition containing the material for forming resist underlayer film for EUV lithography, and patterning process | RPS4X, SIK3, MLX | DNM1 4060/4885HTT 2857/4885KMT2A 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.